Investing.com -- Adicet Bio shares jumped 6.4% premarket after the company announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to its investigational therapy ADI-001 for the treatment of systemic sclerosis (SSc).
ADI-001 is a CAR T cell therapy that targets CD20 to treat autoimmune diseases.
Fast Track Designation is intended to accelerate the development and regulatory review of drugs aimed at treating serious conditions with unmet medical needs.
The designation provides Adicet Bio with several potential advantages, including more frequent FDA interactions, eligibility for priority review, and the possibility of accelerated approval if clinical data supports it.
This milestone strengthens Adicet Bio’s position in the cell therapy space, particularly in autoimmune diseases and cancer, where the company is focused on developing novel gamma delta T cell-based treatments.
The stock’s premarket jump reflects investor optimism about the regulatory progress of ADI-001 and its potential to address systemic sclerosis.
Related Articles
Adicet Bio shares rise on FDA Fast Track Designation for ADI-001
Target and Warby Parker team up for in-store eyewear shops
Microsoft urges Trump to overhaul Biden's last AI chip export curbs
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。